- NCIt
- C3487
Loading cancer entity…
Loading cancer entity…
Clinical trials
96 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05880160 | Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction(HER-SAFE) | completed | N/A | 90 | University College, LondonOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02619682 | Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 25, 2026 |
| clinicaltrials |
| NCT05564390 | MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | recruiting | Phase 2 | 2,000 | National Cancer Institute (NCI)NIH | 3 | Sep 25, 2026 | clinicaltrials |
| NCT07012044 | A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia | recruiting | Phase 1 | 47 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05554406 | Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) | recruiting | Phase 2 | 335 | National Cancer Institute (NCI)NIH | 3 | Sep 22, 2026 | clinicaltrials |
| NCT04128501 | Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | active not recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01861314 | Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT03953898 | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation | active not recruiting | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04782752 | Non-ablative Oligofractionated Radiation Therapy Before Surgical Transplantation As Radiovaccination(NORThSTAR) | recruiting | N/A | 30 | Marc de PerrotOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04269213 | CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old | completed | Phase 2 | 21 | Roswell Park Cancer InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04339738 | Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma | active not recruiting | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 2 | Sep 8, 2026 | clinicaltrials |
| NCT01885689 | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia | active not recruiting | Phase 2 | 72 | City of Hope Medical CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03131934 | Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant(ITREC) | completed | Early Phase 1 | 4 | University College, LondonOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT02727803 | Personalized NK Cell Therapy in CBT | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04062266 | AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT00093470 | Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission | completed | Phase 3 | 144 | National Cancer Institute (NCI)NIH | 3 | Jul 14, 2026 | clinicaltrials |
| NCT04376229 | Proton Radiation Therapy Registry | recruiting | — | 5,000 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04802161 | Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes | active not recruiting | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07675967 | Clonal Hematopoiesis Chemotherapy and Radiation Effects Study(CH CARE) | recruiting | — | 5,000 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07563010 | Menin-Inhibitor Targeted Maintenance in AML | not yet recruiting | Phase 2 | 146 | Center for International Blood and Marrow Transplant ResearchNETWORK | 0 | Jun 22, 2026 | clinicaltrials |
| NCT05384288 | Response to Influenza Vaccination in Pediatric Oncology Patients | recruiting | — | 150 | St. Jude Children's Research HospitalOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04550442 | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | terminated | Phase 1 / Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05146739 | Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03330821 | Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 53 | University of Southern CaliforniaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05663502 | Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers | recruiting | — | 200 | AIDS Malignancy ConsortiumNETWORK | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07444216 | A Longitudinal Photo-Narrative Exploration of Hope During Phase 1/2 Clinical Trials For Pediatric Cancer | recruiting | — | 100 | St. Jude Children's Research HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT01627041 | Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia | active not recruiting | Phase 2 | 178 | National Cancer Institute (NCI)NIH | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03009240 | Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | completed | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06295965 | Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study | recruiting | — | 2,000 | University of WashingtonOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04237623 | GM-CSF With Post-Transplant Cyclophosphamide | recruiting | Phase 2 | 38 | Northside Hospital, Inc.OTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05164016 | Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients | completed | — | 21 | St. Jude Children's Research HospitalOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05554419 | Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) | not yet recruiting | Phase 2 | 184 | National Cancer Institute (NCI)NIH | 0 | Apr 13, 2026 | clinicaltrials |
| NCT05292664 | Venetoclax Basket Trial for High Risk Hematologic Malignancies | recruiting | Phase 1 | 30 | Andrew E. Place, MDOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT03226418 | Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia | completed | Phase 2 | 75 | University of NebraskaOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05316701 | Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies(Orca-T) | active not recruiting | Phase 3 | 187 | Orca Biosystems, Inc.INDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04160052 | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome | terminated | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06950034 | A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) | recruiting | Phase 1 | 105 | Solu Therapeutics, IncINDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT05684367 | Exercise to ReGain Stamina and Energy (The EXERGISE Study) | recruiting | N/A | 24 | University of FloridaOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT02381548 | Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia | terminated | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Jan 30, 2026 | clinicaltrials |
| NCT04151342 | CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)(CARMA-BROS) | recruiting | — | 5,500 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT01139970 | Veliparib and Temozolomide in Treating Patients With Acute Leukemia | completed | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06143839 | VYxeoS Liposomal Italian Observational Study iN the Real Practice(VYSION) | completed | — | 113 | Jazz PharmaceuticalsINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT01760655 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies | completed | Phase 2 | 62 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT02438761 | PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)(5) | terminated | Phase 2 | 10 | Institut CurieOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT02397720 | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06998823 | The Effect of Survival, Response and Microbiota Change in Different Therapy Under Probiotic Supplement | recruiting | N/A | 120 | Chang Gung Memorial HospitalOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT02658487 | Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia(VITAL) | completed | Phase 2 | 42 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 15, 2025 | clinicaltrials |
Data updated 8 hours agoSource updated Sep 28, 2026source: clinicaltrials